GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tetraphase Pharmaceuticals Inc (NAS:TTPH) » Definitions » Current Ratio

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Current Ratio : 3.66 (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Tetraphase Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tetraphase Pharmaceuticals's current ratio for the quarter that ended in Mar. 2020 was 3.66.

Tetraphase Pharmaceuticals has a current ratio of 3.66. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Tetraphase Pharmaceuticals's Current Ratio or its related term are showing as below:

TTPH's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.79
* Ranked among companies with meaningful Current Ratio only.

Tetraphase Pharmaceuticals Current Ratio Historical Data

The historical data trend for Tetraphase Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tetraphase Pharmaceuticals Current Ratio Chart

Tetraphase Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.98 13.09 7.96 7.78 2.71

Tetraphase Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.28 4.10 2.70 2.71 3.66

Competitive Comparison of Tetraphase Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tetraphase Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's Current Ratio falls into.



Tetraphase Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Tetraphase Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Current Ratio (A: Dec. 2019 )=Total Current Assets (A: Dec. 2019 )/Total Current Liabilities (A: Dec. 2019 )
=26.493/9.77
=2.71

Tetraphase Pharmaceuticals's Current Ratio for the quarter that ended in Mar. 2020 is calculated as

Current Ratio (Q: Mar. 2020 )=Total Current Assets (Q: Mar. 2020 )/Total Current Liabilities (Q: Mar. 2020 )
=29.818/8.144
=3.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tetraphase Pharmaceuticals  (NAS:TTPH) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Tetraphase Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.
Executives
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Larry G. Edwards director, officer: See Remarks C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Geraldine Henwood director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David Charles Lubner officer: SVP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Headlines

From GuruFocus